Revenue and Financial Performance - Rafael Holdings reported a product revenue of $0.1 million for the three months ended January 31, 2026, and $0.3 million for the six months ended January 31, 2026, compared to $0 for the same periods in 2025, attributed to Cyclo's product revenue post-merger and sales from Rafael Medical Devices [289]. - The Healthcare segment incurred a loss from operations of $6.7 million for the three months ended January 31, 2026, which is an increase of 105% compared to a loss of $3.3 million for the same period in 2025 [288]. - Infusion Technology segment reported a revenue decrease of 100% to $0 for the three months ended January 31, 2026, compared to $51,000 in the same period of 2025 [293]. - Consolidated net loss attributable to Rafael Holdings, Inc. was $6.4 million for the three months ended January 31, 2026, a 38% increase from a net loss of $4.6 million in the same period of 2025 [298]. - Cash used in operating activities was $14.3 million for the six months ended January 31, 2026, significantly impacted by a net loss of $16.1 million [309]. - Total assets decreased by 13% to $99.3 million as of January 31, 2026, compared to $114.1 million as of July 31, 2025 [307]. - Interest income decreased by 30% to $0.7 million for the six months ended January 31, 2026, compared to $1.1 million in the same period of 2025 [299]. Expenses and Costs - Research and development expenses for the Healthcare segment increased to $4.0 million for the three months ended January 31, 2026, primarily due to Cyclo's expenses, compared to a significantly lower amount in the previous year [292]. - General and administrative expenses for the three months ended January 31, 2026, decreased by 7% to $2.2 million, mainly due to reductions in payroll and professional fees, despite the inclusion of Cyclo's expenses [291]. - General and administrative expenses in the Infusion Technology segment decreased by 89% to $29,000 for the six months ended January 31, 2026, compared to $255,000 in the same period of 2025 [293]. Investments and Strategic Initiatives - The company is focusing on completing the development of Trappsol® Cyclo™ and expanding its investment portfolio in therapeutics addressing high unmet medical needs [277]. - LipoMedix, with a 95% ownership interest, is exploring strategic options for its lead candidate, including potential licensing and collaborations [280]. - Rafael Medical Devices raised approximately $925,000 by selling a 31.6% equity interest to third parties in August 2023 [284]. Regulatory and Milestones - The FDA granted substantial equivalence determination for the VECTR System, which is intended for minimally invasive surgeries, marking a significant milestone for Rafael Medical Devices [284]. - The merger with Cyclo was completed on March 25, 2025, making Cyclo a wholly-owned subsidiary of Rafael Holdings [279]. Cash Flow and Financial Position - Cash and cash equivalents decreased by 28% to $37.8 million as of January 31, 2026, down from $52.8 million as of July 31, 2025 [307]. - Cash used in investing activities for the six months ended January 31, 2026 was primarily due to the purchase of investments in Nina Medical for $0.8 million [311]. - Revenue from tenants located in Israel represented 38% of consolidated revenues for the six months ended January 31, 2026, compared to 75% for the same period in 2025 [319]. Accounting and Financial Reporting - The company applies significant accounting policies consistently to report operating results and financial condition in conformity with U.S. GAAP [315]. - The company evaluates critical accounting estimates and assumptions on an ongoing basis, which may involve significant management judgments [316]. - The company does not anticipate paying dividends on common stock until achieving sustainable profitability and retaining certain minimum cash reserves [314]. - The company has no off-balance sheet arrangements that are likely to affect its financial condition or results of operations [317]. - The net amount of exposure to foreign currency exchange rate changes at the end of each reporting period is generally not material [319].

Financial Performance - Rafael Holdings reported a net loss of $6.4 million, or $0.13 per share, for the three months ended January 31, 2026, compared to a net loss of $4.6 million, or $0.19 per share, in the same period last year [6]. - For the six months ended January 31, 2026, the net loss attributable to Rafael Holdings was $16.2 million, or $0.32 per share, compared to a net loss of $13.6 million, or $0.57 per share, in the prior year [9]. - The company reported a loss from operations of $6.7 million for the three months ended January 31, 2026, compared to a loss of $6.6 million in the same period last year [18]. Revenue and Expenses - Total revenue for the three months ended January 31, 2026, was $211,000, up from $77,000 in the same period last year, driven by product revenue of $125,000 [18]. - Research and development expenses increased to $4.5 million for the three months ended January 31, 2026, from $0.9 million in the prior year, primarily due to the consolidation of Cyclo Therapeutic's expenses following its acquisition [7]. - General and administrative expenses decreased to $2.3 million for the three months ended January 31, 2026, from $2.6 million in the prior year [8]. Cash and Assets - Cash and cash equivalents as of January 31, 2026, were $37.8 million, down from $52.8 million as of July 31, 2025 [5]. - The total assets of Rafael Holdings as of January 31, 2026, were $99.3 million, down from $114.1 million as of July 31, 2025 [16]. Clinical Trials and Pipeline - The company is on track to complete a 96-week Phase 3 clinical trial for Trappsol Cyclo™ and expects to report preliminary top-line results in the third quarter of 2026 [4]. - Rafael Holdings continues to evaluate the potential of its pipeline, including ongoing clinical trials for its lead candidate, Trappsol Cyclo™ [13].

Core Viewpoint - Rafael Holdings, Inc. reported its financial results for the second quarter of fiscal year 2026, highlighting ongoing clinical trials and financial performance, including increased net losses attributed to the consolidation of Cyclo Therapeutics' expenses following its acquisition. Financial Performance - As of January 31, 2026, the company had cash and cash equivalents of $37.8 million [4] - For the three months ended January 31, 2026, the net loss attributable to Rafael Holdings was $6.4 million, or $0.13 per share, compared to a net loss of $4.6 million, or $0.19 per share in the same period last year [5] - Research and development expenses for the same period were $4.5 million, up from $0.9 million year-over-year, primarily due to the inclusion of Cyclo's expenses [6] - General and administrative expenses were $2.3 million, a decrease from $2.6 million in the prior year, attributed to reduced payroll and professional fees [7] - For the six months ended January 31, 2026, the net loss was $16.2 million, or $0.32 per share, compared to a net loss of $13.6 million, or $0.57 per share in the previous year [8] Clinical Development - The company is progressing with its pivotal Phase 3 TransportNPC™ study evaluating Trappsol Cyclo™ for Niemann-Pick Disease Type C1, with the Data Monitoring Committee recommending continuation after reviewing safety and efficacy data at 48 weeks [2] - The Phase 3 clinical trial is the largest ever conducted for this indication, with preliminary top-line results expected in the third quarter of 2026 [3] Company Overview - Rafael Holdings, Inc. is a biotechnology company focused on developing pharmaceuticals and holding interests in clinical and early-stage companies [11] - The lead candidate, Trappsol Cyclo™, is under evaluation for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disorder [11]

Core Insights - Rafael Holdings, Inc. (RFL) is engaged in the development and commercialization of novel cancer therapies within a competitive biotechnology landscape [1] - The company's Return on Invested Capital (ROIC) is -34.90%, significantly lower than its Weighted Average Cost of Capital (WACC) of 8.08% [2][6] - All companies in the peer group, including RFL, are generating returns below their cost of capital, with Verrica Pharmaceuticals Inc. (VRCA) showing relatively better efficiency [5][6] Financial Metrics Comparison - RFL's ROIC to WACC ratio is -4.32, indicating insufficient returns to cover capital costs [2] - Scholar Rock Holding Corporation (SRRK) has a ROIC of -101.98% and a WACC of 6.91%, resulting in a ROIC to WACC ratio of -14.75, which is less efficient than RFL [3] - Evelo Biosciences, Inc. (EVLO) has the lowest ROIC to WACC ratio at -22.10, with a ROIC of -199.73% against a WACC of 9.04% [3][6] - Verrica Pharmaceuticals Inc. (VRCA) has a ROIC of -65.23% and a WACC of 16.08%, yielding the highest ROIC to WACC ratio among peers at -4.06 [4] - Replimune Group, Inc. (REPL) shows a ROIC of -94.11% and a WACC of 7.63%, resulting in a ROIC to WACC ratio of -12.34 [4]

Company Overview - Rafael Holdings, Inc. (NYSE:RFL) focuses on the development and commercialization of novel cancer therapies through its subsidiaries, emphasizing oncology drug research and development [1] Financial Performance - RFL's Return on Invested Capital (ROIC) is -34.90%, significantly lower than its Weighted Average Cost of Capital (WACC) of 7.93%, resulting in a ROIC to WACC ratio of -4.40, indicating the company is not generating returns above its cost of capital [2] - Compared to its peers, RFL demonstrates relatively more efficient capital utilization despite the negative ROIC [2] Peer Comparison - Scholar Rock Holding Corporation (SRRK) has a ROIC of -101.98% and a WACC of 6.82%, leading to a ROIC to WACC ratio of -14.96, indicating less efficient capital utilization compared to RFL [3] - Evelo Biosciences, Inc. (EVLO) shows a ROIC of -199.73% and a WACC of 9.04%, resulting in a ROIC to WACC ratio of -22.10, further highlighting its inefficiency [3] - Verrica Pharmaceuticals Inc. (VRCA) is the most efficient among peers with a ROIC to WACC ratio of -4.13, indicating better capital efficiency despite all companies having negative ratios [4] - Replimune Group, Inc. (REPL) has a ROIC of -71.09% and a WACC of 7.47%, resulting in a ROIC to WACC ratio of -9.52, showing less favorable performance [4]

Core Insights - Mt. San Rafael Hospital and Clinics (MSRHC) has selected Oracle Health to enhance its electronic health record (EHR) platform and improve clinical and financial performance [1][2] - The integration of Oracle Health Clinical AI Agent aims to reduce administrative burdens, allowing healthcare providers to focus more on patient care [2][3] - MSRHC's collaboration with Oracle Health is seen as a strategic investment in the future of rural healthcare, enhancing efficiency and patient experience [3][5] Company Overview - MSRHC is a 25-bed critical access hospital located in Trinidad, Colorado, recognized as one of the Top 20 critical access hospitals in the nation [6][7] - The hospital has achieved HIMSS Stage 6 designation, reflecting its commitment to clinical quality, digital maturity, and patient safety [7] - MSRHC is dedicated to expanding access to high-quality healthcare services in southern Colorado and is a leader in rural healthcare innovation [8] Technology Implementation - MSRHC will implement Oracle Health Foundation EHR along with Oracle Health Clinical AI Agent, which automates clinical documentation through voice-driven technology [2][4] - The Oracle Health Seamless Exchange will enable MSRHC to securely aggregate patient data from various sources, enhancing clinical decision-making [4][5] - The AI integration allows physicians to engage in natural conversations with patients while the system automatically drafts clinical notes, reducing manual data entry [3][4] Strategic Goals - The partnership with Oracle Health is aimed at optimizing clinical and financial outcomes for rural healthcare providers [5] - MSRHC's investment in modern technology and facilities is part of its commitment to delivering exceptional care and improving operational sustainability [8]

Revenue Performance - Rafael Holdings reported a 100% increase in product revenue for the Healthcare segment, reaching approximately $0.2 million for the three months ended October 31, 2025, compared to $0 for the same period in 2024[268]. - The Infusion Technology segment reported a 100% decrease in revenue, falling to $0 for the three months ended October 31, 2025, compared to $51,000 in the same period in 2024[271]. - The Real Estate segment generated rental income of $56,000 from third parties, reflecting a 12% increase compared to $50,000 in the prior year[273]. - Revenue from tenants located in Israel represented 36% of consolidated revenues for the three months ended October 31, 2025, down from 60% in 2024[293]. Expenses - Research and development expenses surged by 545% to $7.5 million for the Healthcare segment in the three months ended October 31, 2025, primarily due to the consolidation of Cyclo's expenses[267]. - General and administrative expenses for the Healthcare segment increased by 20% to $2.8 million, largely due to the inclusion of Cyclo's expenses[269]. - General and administrative expenses in the Real Estate segment decreased by 53% to $57,000, primarily due to reduced real estate taxes[273]. - Consolidated net loss for the three months ended October 31, 2025, was $9.8 million, a 6% increase from the net loss of $9.2 million in the same period of 2024[274]. - Loss from operations increased by 164% to $10.1 million for the three months ended October 31, 2025, compared to a loss of $3.8 million in 2024[274]. - Interest income decreased by 30% to $0.4 million for the three months ended October 31, 2025, compared to $0.6 million in 2024[274]. Cash Flow and Working Capital - Cash and cash equivalents decreased by 14% to $45.5 million as of October 31, 2025, down from $52.8 million on July 31, 2025[282]. - Working capital decreased by 20% to $36.2 million as of October 31, 2025, compared to $45.1 million on July 31, 2025[282]. - Cash used in operating activities was $6.8 million for the three months ended October 31, 2025, a 124% increase from $3.0 million used in the same period of 2024[284]. - Cash flows from investing activities for the three months ended October 31, 2025, included a purchase of preferred shares for $0.5 million[286]. Assets and Holdings - Total assets decreased by 8% to $105.4 million as of October 31, 2025, from $114.1 million on July 31, 2025[282]. - Rafael Holdings holds a 95% interest in LipoMedix and a 67% interest in Cornerstone, with ongoing evaluations of these holdings to focus resources on core assets[260][262]. Strategic Developments - The FDA granted substantial equivalence determination for the VECTR System, which is designed for minimally invasive surgeries, marking a significant milestone for Rafael Medical Devices[263]. - The merger with Cyclo was completed on March 25, 2025, making Cyclo a wholly-owned subsidiary and enhancing the company's product pipeline[259]. - The company is strategically focusing on the development of Trappsol® Cyclo™ for Niemann-Pick Disease Type C1, with ongoing Phase 3 clinical trials[257].

Financial Performance - Rafael Holdings reported a net loss of $9.8 million, or $0.19 per share, for the first quarter of fiscal 2026, compared to a net loss of $9.0 million, or $0.37 per share, in the same period last year[5]. - Total revenues for the quarter were $240,000, up from $128,000 in the same quarter of the previous year[15]. - Operating loss for the quarter was $10.1 million, compared to an operating loss of $3.8 million in the prior year[15]. - General and administrative expenses rose to $2.8 million for the quarter, compared to $2.5 million in the same period last year[7]. Research and Development - Research and development expenses increased to $7.5 million for the three months ended October 31, 2025, from $1.3 million in the prior year, primarily due to the consolidation of Cyclo Therapeutics' expenses following its acquisition[6]. - The company is progressing in its pivotal Phase 3 TransportNPC™ study for Trappsol Cyclo™, which is aimed at treating Niemann-Pick Disease Type C1[3]. Cash and Assets - Cash and cash equivalents as of October 31, 2025, were $45.5 million, down from $52.8 million as of July 31, 2025[4]. - Total current assets decreased to $48.3 million as of October 31, 2025, from $56.7 million as of July 31, 2025[12]. - The accumulated deficit increased to $242.1 million as of October 31, 2025, from $232.3 million as of July 31, 2025[12]. - Total equity attributable to Rafael Holdings decreased to $85.2 million as of October 31, 2025, from $94.4 million as of July 31, 2025[12].

Core Viewpoint - Rafael Holdings, Inc. reported its financial results for the first quarter of fiscal year 2026, highlighting a net loss and increased expenses due to the acquisition of Cyclo Therapeutics, while also emphasizing progress in its clinical trials for Trappsol® Cyclo™ [1][4][5]. Financial Performance - As of October 31, 2025, the company had cash and cash equivalents of $45.5 million [3]. - For the three months ended October 31, 2025, the net loss attributable to Rafael Holdings was $9.8 million, or $0.19 per share, compared to a net loss of $9.0 million, or $0.37 per share in the same period last year [4][13]. - Research and development expenses increased to $7.5 million from $1.3 million year-over-year, primarily due to the inclusion of Cyclo's expenses following its acquisition [5]. - General and administrative expenses rose to $2.8 million from $2.5 million year-over-year, also reflecting Cyclo's expenses [6]. Clinical Development - The company is advancing its pivotal Phase 3 TransportNPC™ study for Trappsol® Cyclo™, which is aimed at treating Niemann-Pick Disease Type C1. The Data Monitoring Committee recommended continuing the study after reviewing safety and efficacy data at 48 weeks [2]. Company Overview - Rafael Holdings, Inc. is a biotechnology company focused on developing pharmaceuticals and holding interests in clinical and early-stage companies. Its lead candidate, Trappsol® Cyclo™, is currently in a pivotal Phase 3 clinical trial for Niemann-Pick Disease Type C1 [7]. Balance Sheet Highlights - Total assets as of October 31, 2025, were $105.4 million, down from $114.1 million as of July 31, 2025 [10][11]. - Total liabilities were reported at $27.0 million, with current liabilities at $12.1 million [10]. - Total equity attributable to Rafael Holdings, Inc. decreased to $85.2 million from $94.4 million [11]. Income Statement Summary - Revenues for the three months ended October 31, 2025, were $240,000, compared to $128,000 in the prior year [12]. - The operating loss for the period was $10.1 million, compared to a loss of $3.8 million in the same period last year [12]. - The net loss attributable to Rafael Holdings, Inc. was $9.8 million, compared to $9.0 million in the previous year [13].

Group 1 - The Raytheon-Rafael Protection Systems (R2S) joint venture has secured a $1.25 billion contract to supply Israel with Tamir surface-to-air missiles, marking a significant milestone for both companies [1][3] - A new facility in East Camden, Arkansas, was established with a $33 million investment to support the production of Iron Dome interceptors, specifically the Tamir missiles for both the Iron Dome and its U.S. variant, SkyHunter [2][3] - The Iron Dome system, operational since 2011, has demonstrated a success rate exceeding 95% in intercepting threats, showcasing its effectiveness in combat [3] Group 2 - Raytheon, as part of RTX, is a leading provider of defense solutions, focusing on integrated air and missile defense, smart weapons, and advanced sensors [5][6] - Rafael Advanced Defense Systems Ltd. is one of Israel's largest defense companies, providing a wide range of high-tech defense systems for various applications [4] - RTX, the world's largest aerospace and defense company, reported sales exceeding $80 billion for 2024 and employs over 185,000 people globally [6]